FGFR2 is one of the best studied targets with regard to therapeutic options in CCA, and multiple FGFR inhibitors have received FDA approval for the indication of CCA, including pemigatinib, futibatinib, and infigratinib [49]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.